VYNE Therapeutics Inc. (VYNE): Price and Financial Metrics
GET POWR RATINGS... FREE!
VYNE Stock Summary
- With a year-over-year growth in debt of -99.91%, VYNE THERAPEUTICS INC's debt growth rate surpasses only 1.22% of about US stocks.
- Revenue growth over the past 12 months for VYNE THERAPEUTICS INC comes in at -58.06%, a number that bests only 3.05% of the US stocks we're tracking.
- Shareholder yield, a measure of how much is returned to shareholders via dividends and share repurchases, for VYNE comes in at 246.09% -- higher than that of 98.73% of stocks in our set.
- Stocks that are quantitatively similar to VYNE, based on their financial statements, market capitalization, and price volatility, are WISA, AAOI, MRIN, EYPT, and IPGP.
- Visit VYNE's SEC page to see the company's official filings. To visit the company's web site, go to www.menlotherapeutics.com.
VYNE Valuation Summary
- VYNE's price/sales ratio is 2.1; this is 10.53% higher than that of the median Healthcare stock.
- VYNE's EV/EBIT ratio has moved up 43.5 over the prior 57 months.
Below are key valuation metrics over time for VYNE.
| Stock | Date | P/S | P/B | P/E | EV/EBIT |
|---|---|---|---|---|---|
| VYNE | 2022-09-23 | 2.1 | 0.3 | -0.4 | 0.9 |
| VYNE | 2022-09-22 | 2.1 | 0.3 | -0.4 | 0.9 |
| VYNE | 2022-09-21 | 2.2 | 0.3 | -0.4 | 0.8 |
| VYNE | 2022-09-20 | 2.3 | 0.3 | -0.4 | 0.8 |
| VYNE | 2022-09-19 | 2.3 | 0.3 | -0.4 | 0.8 |
| VYNE | 2022-09-16 | 2.4 | 0.3 | -0.4 | 0.8 |
VYNE's Quality Factors
The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.- VYNE has a Quality Grade of D, ranking ahead of 14.91% of graded US stocks.
- VYNE's asset turnover comes in at 0.132 -- ranking 235th of 681 Pharmaceutical Products stocks.
- 500 - Internal server error
The table below shows VYNE's key quality metrics over time.
| Period | Asset Turnover | Gross Margin | ROIC |
|---|---|---|---|
| 2021-06-30 | 0.132 | 0.856 | -2.324 |
| 2021-03-31 | 0.194 | 0.926 | -5.086 |
| 2020-12-31 | 0.170 | 0.934 | -4.672 |
| 2020-09-30 | 0.140 | 0.949 | -4.901 |
| 2020-06-30 | 0.115 | 0.964 | -4.606 |
| 2020-03-31 | 0.016 | 0.845 | -1.853 |
VYNE Price Target
For more insight on analysts targets of VYNE, see our VYNE price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.
| Average Price Target | $5.00 | Average Broker Recommendation | 1.58 (Moderate Buy) |
VYNE Stock Price Chart Interactive Chart >
VYNE Price/Volume Stats
| Current price | $0.25 | 52-week high | $1.75 |
| Prev. close | $0.24 | 52-week low | $0.22 |
| Day low | $0.24 | Volume | 62,715 |
| Day high | $0.27 | Avg. volume | 660,651 |
| 50-day MA | $0.31 | Dividend yield | N/A |
| 200-day MA | $0.52 | Market Cap | 14.33M |
VYNE Therapeutics Inc. (VYNE) Company Bio
VYNE Therapeutics Inc. operates as a clinical stage bio-pharmaceutical company. The Company develops medicines and therapies for the treatment of chronic pruritus and cough. VYNE Therapeutics serves customers worldwide.
Latest VYNE News From Around the Web
Below are the latest news stories about VYNE THERAPEUTICS INC that investors may wish to consider to help them evaluate VYNE as an investment opportunity.
VYNE Therapeutics to Present at the H.C. Wainwright 24th Annual Global Investment ConferenceSeptember 13, 2022BRIDGEWATER, N.J., Sept. 06, 2022 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”), a biopharmaceutical company developing proprietary, innovative, and differentiated therapies for the treatment of immuno-inflammatory conditions, today announced that David Domzalski, President and Chief Executive Officer of VYNE, is scheduled to participate at the H.C. Wainwright 24th Annual Global Investment Conference (Hybrid) on September 13, 2022. Manageme |
VYNE Therapeutics Reports Second Quarter 2022 Financial ResultsBRIDGEWATER, N.J., Aug. 12, 2022 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”), a biopharmaceutical company developing proprietary, innovative, and differentiated therapies for the treatment of immuno-inflammatory conditions, today announced financial results for the three and six months ended June 30, 2022. "We believe our BET inhibitor platform holds unique and significant potential to address several immuno-inflammatory diseases, and we look forward to co |
Analysts Offer Insights on Healthcare Companies: VYNE Therapeutics (VYNE) and MiNK Therapeutics (INKT)There's a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on VYNE Therapeutics (VYNE – Research Report) and MiNK Therapeutics (INKT – Research Report) with bullish sentiments. VYNE Therapeutics (VYNE) In a report released today, Joseph Pantginis from H.C. Wainwright maintained a Buy rating on VYNE Therapeutics, with a price target of $1.50. The company's shares closed last Wednesday at $0.26. According to TipRanks. |
VYNE Therapeutics Announces Results from its Phase 2a Trial of FMX114 for the Treatment of Mild-to-Moderate Atopic DermatitisBRIDGEWATER, N.J., Aug. 10, 2022 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”), a biopharmaceutical company developing proprietary, innovative, and differentiated therapies for the treatment of immuno-inflammatory conditions, today announced results from the Phase 2a segment of a Phase 1b/2a clinical trial evaluating FMX114 for the treatment of mild-to-moderate atopic dermatitis (“AD”). Study VY2021-01 did not meet its primary endpoint based on the absolute |
VYNE Therapeutics to Present at the B&T Cell-Mediated Autoimmune Disease Drug Development ConferenceBRIDGEWATER, N.J., July 19, 2022 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”), a biopharmaceutical company developing proprietary, innovative, and differentiated therapies for the treatment of immuno-inflammatory conditions, today announced that Iain Stuart, Ph.D., Chief Scientific Officer of VYNE, will be presenting at the B&T Cell-Mediated Autoimmune Disease Drug Development Conference (in-person) on July 27, 2022. B&T Cell-Mediated Autoimmune Disease Dru |
VYNE Price Returns
| 1-mo | N/A |
| 3-mo | -45.69% |
| 6-mo | -57.76% |
| 1-year | -78.99% |
| 3-year | -98.57% |
| 5-year | N/A |
| YTD | -75.49% |
| 2021 | -83.86% |
| 2020 | -65.95% |
| 2019 | N/A |
| 2018 | N/A |
| 2017 | N/A |
Loading social stream, please wait...